BioSpace News Archive

Biophytis SA announced that it is presenting new preclinical efficacy data for its product Sarconeos in SMA at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022.

Encision Inc. announced financial results for its fiscal 2022 fourth quarter that ended March 31, 2022.

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE an open-label extension clinical study designed to assess the long-term safety and tolerability of reldesemtiv in people with amyotrophic lateral sclerosis (ALS).

Presentation by Pionyr Chief Medical Officer Leonard Reyno, M.D., features leading research in modulating innate immunity to treat cancer.

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that the first patient has been enrolled in the Phase 2a GALLANT-1 trial ( NCT05240131 ).

Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 ® (devimistat) targeting carcinoma catabolism.

Pliant Therapeutics, Inc. today announced the dvancement of a fibrosis-directed integrin target into development as part of the Company’s 2019 research and development collaboration with Novartis.

Avid Bioservices, Inc., a dedicated contract development and manufacturing organization focused on development and CGMP manufacturing services for biotechnology and pharmaceutical companies, highlighted the companies’ collaborative efforts that enabled the phase-one opening of its new purpose-built, 53,000-square-foot viral vector and CGMP facility in Costa Mesa, California, in only eight months.

LUMINELLE (UVision360, Inc.), an innovative FEMTECH/ medical device company, announces today new additions to their Board of Directors.